Analyzing the Most Promising Drugs That Will Lose Patent in the US & EU in 2022
Genital Warts
VP-102: A Potential Emerging Drug for...

Warts are small, benign fleshy growths of the skin or mucous membranes caused by various strains of the hum...

Biogen terminates ALS Pact with Karyo...

Biogen terminates USD 217 Million ALS Pact with Karyopharm Biogen has backed out of the four-year-old partn...

Top Drugs Losing Patent Protection in 2022
Analyzing the Most Promising Drugs Th...

Patent protection and expiration is one of the hot topics in the healthcare industry. Patent protection res...

MedTech News for Smithfield, Cynosure, bioMérieux, Artio Medical, HeartPoint, ObvioHealth
Smithfield BioScience and BioCircuit’s Nerve Tape Device; Cynosure-Jeisys Medical’s Partnership; ...

Smithfield BioScience and BioCircuit to Develop New Nerve Tape Device On March 16, 2022, BioCircuit Technologies, a National Institutes of Health (NIH)-funded medical device company primarily f...


pharma news and updates for AstraZeneca, AbbVie, Sandoz, Incyte, Venatorx, and Bayer
AstraZeneca and Merck’s Lynparza; Venatorx’s cefepime-taniborbactam; AbbVie’s Qulipta; AstraZenec...

FDA Clears AstraZeneca and Merck’s Lynparza as an Adjuvant Breast Cancer Therapy The FDA approved the AstraZeneca and Merck drug for a specific group of patients with high-risk early breast can...


MedTech News and Updates for Bioventus, Valencia Technologies, SurGenTec Graftgun, Exactech, PathMaker Neurosystems, Boston Scientific
Bioventus’s StimRouter Pain Management Device; FDA Approval for eCoin Therapy; SurGenTec Launches...

Bioventus Receives 501(k) Clearance for StimRouter Pain Management Device On March 1, 2022, the US Food and Drug Administration (FDA) gave Bioventus' StimRouter Neuromodulation System 510(k) ap...


PARP Inhibitors in Urothelial Carcinoma
PARP inhibitors in Urothelial carcinoma (UC): Hit or miss?

Chemotherapy, immune checkpoint inhibitors, targeted therapies, and antibody-drug conjugates are being used for treating Urothelial Carcinoma(UC) patients and now PARP inhibitors are being studied...


medtech-news-for-zynex-foldax-bd-ge-edwards
Sky Medical’s Geko™ device; Fist Assist Devices obtains Breakthrough Device designation; E...

Sky receives FDA clearance to market the geko™ device for venous insufficiency and ischemia  On December 16, 2021, Sky Medical Technology Ltd, a medical device company, got approval...


pharma-news-for-aslan-iqvia-reata-recordati-eusa
Aslan Pharma – IQVIA collaboration; Reata’s kidney drug bardoxolone; Alzheimer’s Dise...

Aslan Pharmaceuticals enters into a strategic collaboration with IQVIA   ASLAN Pharmaceuticals announced the appointment of IQVIA Biotech, a provider of analytics, technology solution...


Gene Therapies Whitepaper
Gene Therapies

Gene therapies are regarded as one of the potential revolution in the Pharmaceutical field and Healt.....

Toll-like Receptors Agonist
Toll-like Receptors Agoni...

Toll-like Receptors (TLRs) are a type of pattern recognition receptor (PRR) that recognizes pathogen.....

Acute Myeloid Leukemia Newsletter
Acute Myeloid Leukemia...

Acute myeloid leukemia (AML), also called acute myelogenous leukemia and acute nonlymphocytic leukem.....

Editor's Pick
Can denovoSkin Be A Lifesaver for Burn Victims?

Burn is a global public health problem, causing more than 180,000 deaths per year acros...

NexoBrid and its Awaiting US Approval

A Burn takes place when the skin comes into contact with a heat source. Burns can occur...

New Clinical Developments in the Pulmonary Arterial Hypertension Treatment Do...

Pulmonary arterial hypertension is a progressive disease of the lung vascular system, p...

Commercial Roadmap for the Launch: What can Biopharmaceuticals do to Increase...

The Pharma and Biotech Healthcare market has been an ever-changing industry in terms of...

Emerging Market for Organ on a Chip

The organ on a chip is a microfluidic culture device that recapitulates the complicated...